EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372).

Abstract

TPS8571Background: The benefit of adjuvant chemotherapy in NSCLC has plateaued at around 5.4% improvement in 5 year overall survival and is hampered by toxicities having a major impact on treatment...